LTRN ▼ -1.3% - Lantern Pharma Inc. $LTRN - Lantern Pharma Secures USPTO Notice of Allowance for LP?284 Treatment Patent in Aggressive B?Cell Lymphomas Lantern Pharma received a USPTO Notice of Allowance for a patent covering LP-284 in the treatment of aggressive B-cell lymphomas, a validation of its intellectual property position in an oncology area. Despite this positive regulatory development, shares fell 1.3% today, suggesting investors may have already priced in the patent grant or weighted other factors more heavily in their near-term outlook. 22-SEP-2026 07:53 AM ET